Search results
Moderna (MRNA) Secures FDA Nod for mRNA-Based RSV Vaccine
Zacks· 5 days agoThe RSV vaccine is Moderna???s (MRNA) second FDA-approved product. Once the vaccine secures the CDC's recommendation, it will be launched in the 2024-2025 respiratory virus season.
Moderna-Merck skin cancer vaccine shows survival benefit in long-term follow-up
Arizona Daily Sun· 4 days agoModerna and partner Merck & Co said on Monday their cancer vaccine in combination with blockbuster...
Moderna, Merck say vaccine improved survival in patients with deadly skin cancer
NBC New York· 4 days agoModerna and Merck said their experimental vaccine in combination with the therapy Keytruda improved survival and showed durable efficacy in a midstage study in patients with ...
Moderna Scores FDA Approval For Its Second Product - Respiratory Syncytial Virus Vaccine
Benzinga via Yahoo Finance· 7 days agoOn Friday, the FDA approved Moderna Inc’s (NASDAQ:MRNA) mRESVIA (mRNA-1345), an mRNA respiratory...
FDA approves Moderna’s mRNA RSV vaccine for older adults | CNN
CNN.com· 7 days agoThe US Food and Drug Administration has approved another vaccine to help protect older people from...
Novavax's stock surges almost 300% in the past month
Yahoo Finance· 21 hours agoIf approved, Novavax would finally be able to market its only commercially available product during the fall vaccine season, alongside rivals Pfizer...
COVID shots should target JN.1 variant in 2024-25 campaign, US FDA says
Reuters· 2 hours agoThe U.S. Food and Drug Administration on Friday advised COVID-19 vaccine manufacturers that new...
Moderna secures a second FDA vaccine approval as Spikevax sales plummet
Fast Company Magazine· 7 days agoModerna announced on Friday that the U.S. Food and Drug Administration (FDA) has approved its...
Moderna-Merck skin cancer vaccine shows survival benefit in long-term follow-up
Reuters· 4 days ago, opens new tab said on Monday their cancer vaccine in combination with blockbuster cancer therapy...
ASCO: After Keytruda, Merck builds 3-pronged cancer strategy starring Moderna-partnered vaccine
FierceBiotech· 4 days agoAs Keytruda’s 2028 patent cliff looms large, Merck & Co.’s renewed R&D oncology strategy focuses on...